EP1490079A1 - A composition for treating gastric ulcer and a process for preparing the same - Google Patents
A composition for treating gastric ulcer and a process for preparing the sameInfo
- Publication number
- EP1490079A1 EP1490079A1 EP02716987A EP02716987A EP1490079A1 EP 1490079 A1 EP1490079 A1 EP 1490079A1 EP 02716987 A EP02716987 A EP 02716987A EP 02716987 A EP02716987 A EP 02716987A EP 1490079 A1 EP1490079 A1 EP 1490079A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- extract
- composition
- plant part
- piper
- ziniber
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 81
- 208000007107 Stomach Ulcer Diseases 0.000 title claims abstract description 23
- 201000005917 gastric ulcer Diseases 0.000 title claims abstract description 22
- 238000004519 manufacturing process Methods 0.000 title description 2
- 238000000034 method Methods 0.000 claims abstract description 39
- 230000002195 synergetic effect Effects 0.000 claims abstract description 15
- 238000011282 treatment Methods 0.000 claims abstract description 14
- 239000000284 extract Substances 0.000 claims description 70
- 241000196324 Embryophyta Species 0.000 claims description 30
- 244000058084 Aegle marmelos Species 0.000 claims description 15
- 235000003930 Aegle marmelos Nutrition 0.000 claims description 15
- 241001148763 Blechnum Species 0.000 claims description 15
- 244000148716 Feronia limonia Species 0.000 claims description 15
- 235000008756 Feronia limonia Nutrition 0.000 claims description 15
- 235000019510 Long pepper Nutrition 0.000 claims description 15
- 244000237986 Melia azadirachta Species 0.000 claims description 15
- 235000013500 Melia azadirachta Nutrition 0.000 claims description 15
- 240000003455 Piper longum Species 0.000 claims description 15
- 244000203593 Piper nigrum Species 0.000 claims description 15
- 235000008184 Piper nigrum Nutrition 0.000 claims description 15
- 241001083505 Punica Species 0.000 claims description 15
- 240000006365 Vitis vinifera Species 0.000 claims description 15
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 15
- 241000586313 Withania Species 0.000 claims description 15
- 235000001978 Withania somnifera Nutrition 0.000 claims description 15
- 235000002532 grape seed extract Nutrition 0.000 claims description 15
- 239000000654 additive Substances 0.000 claims description 10
- 239000000969 carrier Substances 0.000 claims description 10
- 235000013399 edible fruits Nutrition 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 7
- 241000283690 Bos taurus Species 0.000 claims description 4
- 239000006286 aqueous extract Substances 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 2
- 230000037396 body weight Effects 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 238000007796 conventional method Methods 0.000 claims description 2
- 238000000227 grinding Methods 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 208000025865 Ulcer Diseases 0.000 abstract description 55
- 231100000397 ulcer Toxicity 0.000 abstract description 53
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 abstract description 18
- 229960001340 histamine Drugs 0.000 abstract description 9
- 230000002496 gastric effect Effects 0.000 abstract description 7
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 39
- 229960000381 omeprazole Drugs 0.000 description 39
- 230000004224 protection Effects 0.000 description 34
- 230000000694 effects Effects 0.000 description 29
- 229940079593 drug Drugs 0.000 description 17
- 239000003814 drug Substances 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 11
- 230000003902 lesion Effects 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 230000007721 medicinal effect Effects 0.000 description 10
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 9
- 229960001138 acetylsalicylic acid Drugs 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 210000002784 stomach Anatomy 0.000 description 8
- 239000002398 materia medica Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 208000000718 duodenal ulcer Diseases 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 241000700199 Cavia porcellus Species 0.000 description 3
- 206010062065 Perforated ulcer Diseases 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 230000000767 anti-ulcer Effects 0.000 description 3
- 239000002976 ayurvedic drug Substances 0.000 description 3
- 235000008216 herbs Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 208000001649 Pica Diseases 0.000 description 2
- PQUGCKBLVKJMNT-UHFFFAOYSA-N SC560 Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(C(F)(F)F)=N1 PQUGCKBLVKJMNT-UHFFFAOYSA-N 0.000 description 2
- 230000009858 acid secretion Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000002183 duodenal effect Effects 0.000 description 2
- 239000000321 herbal drug Substances 0.000 description 2
- 230000036269 ulceration Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- COCLLEMEIJQBAG-UHFFFAOYSA-N 8-methylnonyl 2-methylprop-2-enoate Chemical compound CC(C)CCCCCCCOC(=O)C(C)=C COCLLEMEIJQBAG-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241001502381 Budorcas taxicolor Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000000138 effect on histamine Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 239000012674 herbal formulation Substances 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001562 ulcerogenic effect Effects 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 210000002417 xiphoid bone Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/58—Meliaceae (Chinaberry or Mahogany family), e.g. Azadirachta (neem)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Definitions
- the present invention relates to a novel synergistic herbal composition for the treatment of gastric ulcer. More particularly, the present invention relates to a novel synergistic herbal composition which is effective against pyloric ligation induced ulcer model and histamine induced ulcer model. The present invention also relates to a method for the preparation of the composition. The present invention further relates to a process for the treatment of gastric ulcer using the composition.
- the plant part of Ziniber officnale is rhizome.
- the extract is an aqueous extract.
- the plant part of Aegle marmelos, Withania somnifra and Blechnum orintale is root.
- the plant part of Vitis vinifera, Feronia elephantum, Piper nigrum and Piper longum is fruit.
- the plant part of Punica grantum is fruit rind.
- the subject may be administered a single bolus dose or a multiple dose.
- Table 1 represents the effect of Omeprazole (a standard drug) and the new herbal composition (HF) against Cold Restraint Ulcer (CRU) Model.
- Table 2 compares the percentage protection of Omeprazole and the Herbal composition
- Table 4 gives the percentage protection of Omeprazole and the Herbal composition (HF) against aspirin induced ulcer model.
- Table 10 gives the percentage protection of Omeprazole and the Herbal composition (HF) against pyloric ligation induced Ulcer.
- the ulcers are examined under the 5X magnification with the help of magnascope. • Absolute ethanol lesions appears as blackish lesions grouped in patches of varying size, usually parallel to the major axis of the stomach. 5. The lengths of the lesions are measured and summated to give a total lesion score, then calculated and expressed in percentage.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a novel synergistic herbal composition for the treatment of gastric ulcer, amethod for preparing said synergistic herbal composition and a process for the treatment of gastric ulcerusing said composition and more particularly, the present invention relates to a novel synergistic herbal composition which is effective against pyloric ligation induced ulcer model and histamine induced ulcer model.
Description
A COMPOSITION FOR TREATING GASTRIC ULCER AND A PROCESS FOR PREPARING THE SAME
Technical Field The present invention relates to a novel synergistic herbal composition for the treatment of gastric ulcer. More particularly, the present invention relates to a novel synergistic herbal composition which is effective against pyloric ligation induced ulcer model and histamine induced ulcer model. The present invention also relates to a method for the preparation of the composition. The present invention further relates to a process for the treatment of gastric ulcer using the composition. Background Art
Various theories have been proposed with respect to a cause of ulcer in human. In particular, it has been elucidated that stress, taking of non-steroidal anu^inflammatory drugs for curing rheumatic diseases, and the like are closely related to ulcer formation, mainly due to relatively excess gastric or duodenal acid secretion. Accordingly it is important to suppress the acid secretion in order to prevent ulcer formation and to cure it.
On the other hand it has been considered that Helicobacter pylori, which is a rod normally existing in stomach, generates ammonia due to its strong ureas e activity, thereby inducing ulcer. Since it persistently lives within mucus and mucosa, it becomes the greatest cause for recurrence of ulcer. Accordingly, it has been considered that the recurrence of ulcer can be prevented if this bacterium is sterilized.
A reference may be made to K.M. Nadkarni in Indian Materia Medica (1976) Vol. 1, pl287, published by Popular Prakashan Pvt. Ltd., Mumbai and K.R. Kirtikar in Indian Medicinal Plants (1975) Vol. 1, p 608 published by Bishen Singh Mahendrapal Singh, Dehradun for the medicinal properties of Blechnum orintale.
A reference may be made to P.K. Warrier in Indian Medicinal Plants- A compendium of 500 species (1994-1996) Vol. 5, p 396, and The wealth of India (1950-1980), Vol.10 p. 556 published by Council of Scientific and Industrial Research for the various medicinal properties of Vitis vinifera. A reference may be made to K. Narayana Iyer and M. Kolammal in Pharmacognosy of Ayurvedic Drugs (1963) Nol.2, p. 80, published by Department of Pharmacognosy, University of Kerala, Trivandrum and The Wealth of India (1950-1980) Vol. 1, p. 34, published by Council of Scientific and Industrial Research for the various medicinal properties of Aegle marmelos.
A reference may be made to K.M. Nadkarni in Indian Materia Medica (1976) Vol. 1, p. 1239-94, published by Popular Prakashan Pvt. Ltd., Mumbai; K.R. Kirtikar in Indian Medicinal Plants (1975) Vol. 2, p 1776 published by Bishen Singh Mahendrapal Singh, Dehradun; P.K. Warrier in Indian Medicinal Plants- A compendium of 500 species (1994- 1996) Vol. 5, p 409; K. Narayana Iyer and M. Kolammal in Pharmacognosy of Ayurvedic Drugs (1963) Nol.8, p. 34, published by Department of Pharmacognosy, University of Kerala, Trivandrum, The Wealth of India (1950-1980) Nol. 10, p. 585, published by Council of Scientific and Industrial Research and S.S. Handa in Indian Herbal Pharmacopoeia (1998), Nol. 1, p.171, published by Regional Research Laboratory, Jammu and IDMA, Mumbai for the various medicinal properties of Withania somnifra.
A reference may be made to KM. Nadkarni in Indian Materia Medica (1976) Vol. 1, p 536, published by Popular Prakashan Pvt. Ltd., Mumbai; KR. Kirtikar in Indian Medicinal Plants (1975) Vol. 1, p 997 published by Bishen Singh Mahendrapal Singh, Dehradun; P.K. Warrier in Indian Medicinal Plants- A compendium of 500 species (1994-1996) Vol. 3, p. 327-29, and The Wealth of India (1950-1980) Vol. 4, p. 19, published by Council of Scientific and Industrial Research of the various medicinal properties of Feronia elephantum.
A reference may be made to K.M. Nadkarni in Indian Materia Medica (1976) Vol. 1, pi 031, published by Popular Prakashan Pvt. Ltd., Mumbai; P.K. Warrier in Indian Medicinal Plants- A compendium of 500 species (1994-1996) Vol. 4, p 396, and in Illustrated manual of herbal drugs used in Ayurveda (1996) by Y.K.Sarin p.218 for the various medicinal properties of Punica grantum.
A reference may be made to K.M. Nadkarni in Indian Materia Medica (1976) Vol. 1, pl309, published by Popular Prakashan Pvt. Ltd., Mumbai; K.R. Kirtikar in Indian Medicinal Plants (1975) Vol. 4, p 2436 published by Bishen Singh Mahendrapal Singh, Dehradun; P.K. Warrier in Indian Medicinal Plants- A compendium of 500 species (1994- 1996) Vol. 5, p. 431, published by orient Longman, Chennai, and The Ayurvedic Pharmacopoeia of India (1986), Vol. 1, p. 104, published by Ministry of Health and Family Welfare, India for the various medicinal properties of Ziniber officnale. A reference may be made to K.M. Nadkarni in Indian Materia Medica (1976) Vol. 1, p. 478, published by Popular Prakashan Pvt. Ltd., Mumbai; P.K. Warrier in Indian Medicinal Plants- A compendium of 500 species (1994-1996) Vol. 2, p. 368, published by orient Longman, Chennai; Medicinal plants of India (1987) by G.N. Satyavati Nol. 2 p.429 published by Indian Council of Medical Research; The Wealth of India (1950-1980) Nol.
8, p. 98, published by Council of Scientific and Industrial Research, and Y.K. Sarin in
Illustrated manual of herbal drugs used in Ayurveda (1996), p. 268 for the various medicinal properties of Piper nigrum.
A reference may be made to KM. Nadkarni in Indian Materia Medica (1976) Vol. 1, p. 966, published by Popular Prakashan Pvt. Ltd., Mumbai; P.K. Warrier in Indian Medicinal
Plants- A compendium of 500 species (1994-1996) Vol. 4, p. 290, published by orient
Longman, Chennai; K. Narayana Iyer and M. Kolammal in Pharmacognosy of Ayurvedic
Drugs (1963) Nol.9, p. 49, published by Department of Pharmacognosy, University of
Kerala, Trivandrum, and The Wealth of India (1950-1980) Nol. 8, p. 98, published by Council of Scientific and Industrial Research for the various medicinal properties of Piper longum.
A reference may be made to K.R. Kirtikar in Indian Medicinal Plants (1975) Nol. 1, p536-
540 published by Bishen Singh Mahendrapal Singh, Dehradun; P.K. Warrier in Indian
Medicinal Plants- A compendium of 500 species (1994-1996) Nol. 1, p. 203-5, published by orient Longman, and K. Narayana Iyer and M. Kolammal in Pharmacognosy of
Ayurvedic Drugs (1963) Vol.3, p. 23, published by Department of Pharmacognosy,
University of Kerala, Trivandrum for the various medicinal properties of Azadirachta indica.
The composition of the present invention should not be treated as an obvious one as none of the citations are able to provide all the advantages of the present invention. .
Objects of the Invention
The main object of the present invention is to provide a novel synergistic herbal composition for the treatment of gastric ulcer.
Yet another object of the present invention is to provide a process for the preparation of the composition.
Still another object of the present invention is to provide a method for the treatment of gastric ulcer using the composition.
Summary of the Invention
The present invention provides a novel synergistic herbal composition for the treatment of gastric ulcer. More particularly, the present invention relates to a novel synergistic herbal composition which is effective against pyloric ligation induced ulcer model and histamine induced ulcer model. Also, the present invention provides a process for the preparation of the composition. The present invention further provides a method for the treatment of gastric ulcer using said composition.
Detailed Description of the present Invention
In accordance with the first object of the present invention, there is provided a novel synergistic herbal composition for the treatment of gastric ulcer, said composition comprises an extract essentially obtained from one or more parts of Aegle marmelos and Withania somnifra and optionally from one or more parts of Blechnum orintale, Vitis vinifera, Feronia elephantum, Punica grantum, Ziniber ofβcnale, Piper nigrum, Piper longum and Azadirachta indica along with one or more pharmaceutically acceptable additives/carriers .
More particularly, the present invention provides a novel synergistic herbal composition for the treatment of gastric ulcer, said composition essentially comprises 4-10% by wt. of an extract from Aegle marmelos and 4-11% by wt. of an extract from Withania somnifra and optionally comprises 5-8 % by wt. of an extract from Blechnum orintale, 5-11% by wt. of an extract from Vitis vinifera, 5-9% by wt. of an extract from Feronia elephantum, 8-
11%) by wt. of an extract from Punica grantum, 4-9%) by wt. of an extract from Ziniber officnale, 2-11% by wt. of an extract from Piper nigrum, 8-12% by wt. of an extract from
Piper longum and 2-11% by wt. of an extract from Azadirachta indica along with one or more pharmaceutically acceptable additives/carriers.
In an embodiment of the present invention, the extract is an aqueous extract.
In another embodiment of the present invention, the plant part of Aegle marmelos, Withania somnifra and Blechnum orintale is root.
In still another embodiment of the present invention, the plant part of Vitis vinifera,
Feronia elephantum, Piper nigrum and Piper longum is fruit.
In yet another embodiment of the present invention, the plant part of Punica grantum is fruit rind.
In one more embodiment of the present invention, the plant part of Ziniber officnale is rhizome.
In one another embodiment of the present invention, the plant part of Azadirachta indica is bark.
In accordance with the second object of the present invention, there is provided a process for the preparation of the novel synergistic herbal composition for the treatment of gastric ulcer, said process comprising obtaining an extract essentially from one or more parts of
Aegle marmelos and Withania somnifra and optionally from one or more parts of Blechnum orintale, Vitis vinifera, Feronia elephantum, Punica grantum, Ziniber officnale, Piper nigrum, Piper longum and Azadirachta indica and mixing them with one or more pharmaceutically acceptable additives/carriers.
In an embodiment of the present invention, said process extract is obtained by grinding 4- 10% by wt. of an extract from Aegle marmelos and 4-11% by wt. of an extract from Withania somnifra and optionally 5-8 %> by wt. of an extract from Blechnum orintale, 5- 11%) by wt. of an extract from Vitis vinifera, 5-9% by wt. of an extract from Feronia elephantum, 8-11% by wt. of an extract from Punica grantum, 4-9% by wt. of an extract from Ziniber officnale, 2-11% by wt. of an extract from Piper nigrum, 8-12%) by wt. of an extract from Piper longum and 2-11% by wt. of an extract from Azadirachta indica to a fine paste and mixing them with one or more pharmaceutically acceptable additives/carriers . In another embodiment of the present invention, the extract is an aqueous extract.
In still another embodiment of the present invention, the plant part of Aegle marmelos, Withania somnifra and Blechnum orintale is root. In yet another embodiment of the present invention, the plant part of Vitis vinifera, Feronia elephantum, Piper nigrum and Piper longum is fruit. hi one more embodiment of the present invention, the plant part of Punica grantum is fruit rind.
In one another embodiment of the present invention, the plant part of Ziniber officnale is rhizome.
In an embodiment of the present invention, the plant part of Azadirachta indica is bark. In accordance with the third object of the present invention, there is provided a method of treating gastric ulcer in a subject, said method comprises administering an effective amount of the synergistic herbal composition essentially comprises 4-10%o by wt. of an extract from Aegle marmelos and 4-11% by wt. of an extract from Withania somnifra and optionally comprises 5-8 %> by wt. of an extract from Blechnum orintale, 5-11% by wt. of an extract from Vitis vinifera, 5-9% by wt. of an extract from Feronia elephantum, 8-11%> by wt. of an extract from Punica grantum, 4-9%> by wt. of an extract from Ziniber officnale, 2-11% by wt. of an extract from Piper nigrum, 8-12% by wt. of an extract from Piper longum and 2-11%) by wt. of an extract from Azadirachta indica along with one or more pharmaceutically acceptable additives/carriers.
In an embodiment of the present invention, the subject is a mammal including human being. In another embodiment of the present invention, 50 to lOOmg of the composition is administered per Kg of body weight to the subject.
In yet another embodiment of the present invention, the composition can be in the form of tablets, capsules, syrup or by any other form known in the art.
In still another embodiment of the present invention, the composition is administered orally, intra-muscularly, and by any other conventional methods. In one more embodiment of the present invention, the composition may be used for therapeutic as well as prophylactic treatment of gastric ulcer.
In one another embodiment of the present invention, the subject may be administered a single bolus dose or a multiple dose.
Brief Description of the Tables In the tables accompanying the specification,
Table 1 represents the effect of Omeprazole (a standard drug) and the new herbal composition (HF) against Cold Restraint Ulcer (CRU) Model.
Table 2 compares the percentage protection of Omeprazole and the Herbal composition
(HF) against Cold Restraint Ulcer (CRU) Model. Table 3 gives the effect of Omeprazole and the Herbal composition (HF) against Aspirin induced ulcer model.
Table 4 gives the percentage protection of Omeprazole and the Herbal composition (HF) against aspirin induced ulcer model.
Table 5 gives the effect of Omeprazole and the Herbal composition (HF) against histamine induced duodenal ulcer in Guinea pig.
Table 6 gives the percentage protection of Omeprazole and the Herbal composition (HF) against histamine induced duodenal ulcer in Guinea pigs.
Table 7 gives the effect of Omeprazole and the Herbal composition (HF) against Ethanol
Induced Ulcer Model. Table 8 gives the percentage protection of Omeprazole and the Herbal composition (HF) against Alcohol induced Ulcer Model.
Table 9 gives the effect of Omeprazole and the Herbal composition (HF) against pyloric ligation induced Ulcer.
Table 10 gives the percentage protection of Omeprazole and the Herbal composition (HF) against pyloric ligation induced Ulcer.
Table 11 gives the composition of the Herbal composition (HF) of the present invention.
The present invention is further described with reference to the following experiments which are given by way of illustration and therefore should not be construed to limit the scope of the invention in any manner.
Experimental protocol: Invivo experiments:
The Applicants have carried out several experiments under different induced ulcer conditions and the effect of the herbal composition were studied and are tabulated herebelow. The effect of the herbal composition has been compared with respect to a known anti-ulcer drug "Omeprazole".
EXPERIMENT 1: EFFECT ON COLD RESTRAINT ULCERS (CRU) MODEL METHOD: Adult rats of either sex, weighing 150-175 grams are fasted for 24 hours in metallic cages with raised mesh bottoms to prevent coprophagia and were allowed free access to water. The test drugs were administered 45 minutes before immobilizing the animals. The rats were immobilized in the restraint cage and kept at 4°C in BOD incubator for 2 hours (According to the method of Senay and Levine 1967). The animals were sacrificed immediately after the restraint period. The abdomen was cut opened; stomach was taken out and incised along the greater curvature to observe the gastric lesions with the help of Magnascope (5X magnification)
The following arbitrary scoring system was used to grade the severity and intensity of the lesions:
1. Shedding of epithelium = 10 2. Petechial and frank hemorrhages = 20
3. One or two ulcers = 30
4. More than two ulcers = 40
5. Perforated ulcers = 50
The presence of any of these lesions was considered as a positive ulcerogenic response which has been shown as percentage of rats showing gastric lesions. The severity of ulcers is expressed in terms of ulcer index, which is the mean score of gastric lesions of all the rats in a group. The term Ulcer Index is defined as:
Ulcer Index (U.I.) = Us + Up x 10"1 where Us = Mean severity of ulcer score and
Up = Percentage of animals with Ulcer incidences
The percentage protection is calculated as follows:
Percentage protection = (C-T/C) x 100. where C= Number of animals showing ulcer response in control group and T= Number of animals showing ulcer response in test group .
The effect of the herbal composition of the present invention hereafter referred to as "HF" against Cold Restraint Ulcer Model (CRU) is given in Table 1. The effect of the standard drug "Omeprazole" is also given in Table 1 given at the end of the description. Percentage protection of the herbal composition of the present invention (HF) and Omeprazole against CRU model are tabulated in Table 2 given at the end of the description.
INFERENCE: The composition of the present invention is significantly effective in CRU model. EXPERIMENT 2 : EFFECT ON ASPIRIN INDUCED GASTRIC ULCER MODEL Method: Gastric ulceration was induced by aspirin according to the method of
Djahanguiri (1969). Aspirin (150 mg/Kg.) was administered per orally as a suspension in gum-acacia and the animal was sacrificed 5 hr. after the aspirin treatment and the ulcer index with protection index were calculated. The effect of HF against aspirin induced gastric ulcer is given in Table 3. The effect of the standard drug "Omeprazole" is also given in Table 3 given at the end of the description.
Percentage protection of the herbal composition of the present invention (HF) and
Omeprazole against this model are tabulated in Table 4 given at the end of the description.
INFERENCE: The herbal composition of the present invention is effective against Aspirin induced gastric ulcer model.
EXPERIMENT 3: EFFECT ON HISTAMINE INDUCED ULCER MODEL Method:
1. Animals were fasted for 24 hours with access to water. 2. The drug was given orally 1 hour prior to the histamine administration.
3. Histamine was administered in a dose of 0.25 mg/Kg, i.m. at 30 minutes interval for 7 times and it induced 100 % duodenal ulceration in guinea pig (According to the method of Watt and Eagleton 1964).
4. The animals were sacrificed after half an hour of last injection under ether anesthesia.
5. The stomach along with duodenum were removed washed thoroughly and examined for the lesions. Ulcer index and protection index were calculated.
The effect of HF against Histamine induced duodenal ulcer is given in Table 5. The effect of the standard drug "Omeprazole" is also given in Table 5 given at the end of the description.
Percentage protection of the herbal composition of the present invention (HF) and Omeprazole against Histamine induced duodenal ulcer are tabulated in Table 6 given at the end of the description.
INFERENCE: The Herbal composition of the present invention "HF" shows significant anti ulcer effect against this model.
EXPERIMENT 4: EFFECT ON ALCOHOL INDUCED GASTRIC ULCERS IN
RATS Method: 1. Adult rats of either sex were taken; weighing 150 - 175 grams were fasted for 24 hours with free access to water.
2. The test drugs were administered (p.o.) 45 minutes before alcohol administration.
3. 1 ml of chilled absolute alcohol was administered (p.o.) to the rats (According to the Wittetal). ' 4. Immediately after 1 hour, the animals were anesthetized, abdomen was cut opened stomach was taken out and incised along the greater curvature to observe the gastric lesions.
The ulcers are examined under the 5X magnification with the help of magnascope. • Absolute ethanol lesions appears as blackish lesions grouped in patches of varying size, usually parallel to the major axis of the stomach. 5. The lengths of the lesions are measured and summated to give a total lesion score, then calculated and expressed in percentage.
The effect of HF against alcohol induced ulcer model is given in Table7. The effect of the standard drug "Omeprazole" is also given in Table 7 given at the end of the description. Percentage protection of the herbal composition of the present invention (HF) and Omeprazole against alcohol induced ulcer model are tabulated in Table 8 given at the end of the description. INFERENCE: The composition of the present invention does not show any significant effect against alcohol induced gastric ulcer model.
EXPERIMENT 5: EFFECT ON PYLORIC LIGATION INDUCED ULCER MODEL Method:
1. Animals were fasted for 24 hours in the raised mesh bottom cages to prevent coprophagia and were allowed free access to water.
2. The control group of rats was feed with the vehicle and the experimental groups with their respective drags 45 minutes prior to the ligation.
3. The animal was anesthetized, abdomen was cut opened under xiphoid process, and the pyloric portion of the stomach was slightly lifted and ligated avoiding any damage to the adjacent blood vessels (According to the method of Shay et al.
1945).
4. The animals were stitched and kept for 4 hours with free access to water.
5. After 4 hours the animals were sacrificed under ether anesthesia and the stomach was dissected out incised along the greater curvature. 6. The stomach was washed thoroughly and the ulcer index was scored as per in other ulcer models. The effect of HF against pyloric ligation induced ulcer is given in Table 9. The effect of the standard drug "Omeprazole" is also given in Table 9 given at the end of the description. Percentage protection of the herbal composition of the present invention (HF) and Omeprazole against pyloric ligation induced ulcer are tabulated in Table 10 given at the end of the description.
INFERENCE: On comparison, Herbal composition shows high anti ulcer activity. The anti ulcer activity of the herbal composition is higher than that of Omeprazole.
EXPERIMENT 6: HERBS AND PREPARATION OF THE COMPOSITION Method:
For the purpose of conducting animal experiment all the herbs are washed dried and pulverized. All the herbs are taken in the proportion as shown in Table 11. To this water was added and boiled and concentrated to appropriate consistency. The components and their proportions of the standard "herbal composition " (HF) according to one embodiment of the present invention are listed in Tablell given at the end of the description. The parts of the herbs which can be used is also mentioned. The placebo preparation is designed to taste, smell and look like an Ayurvedic herbal formulation.
TABLE 1: Effect of New herbal composition (HF) against Cold Restraint Ulcer Model (CRU) with Omeprazole as a standard drug.
= More than two ulcers; 50 = Perforated ulcers.
TABLE 2: Percentage protection of Herbal composition against Cold Restraint Ulcer Model (CRU) taking Omeprazole as a standard drug.
*The protection of Omeprazole was taken as 100% as it was the standard compound and the percentage protections of other compounds are in respect to the protection of Omeprazole.
= More than two ulcers: 50 = Perforated ulcers.
TABLE 4: Percentage protection of Herbal composition against aspirin induced ulcer model takin Ome razole as a standard dru .
* The protection of Omeprazole was taken as 100% as it was the standard compound and the percentage protections of other compounds are in respect to the protection of Omeprazole.
duodenal ulcer in Guinea pig taking Omeprazole as a standard drug.
COMPOUND PERCENTAGE PROTECTION
Herbal composition 93.07
* Omeprazole 100
* The protection of Omeprazole was taken as 100 % as it was the standard compound and the percentage protections of other compounds are in respect to the protection of Omeprazole. TABLE 7: Effect of Herbal composition against Ethanol Induced Ulcer Model with Omeprazole as a standard drug.
TABLE 8: Percentage protection of Herbal composition against Alcohol induced Ulcer Model taking Omeprazole as a standard drug.
percentage protections of other compounds are in respect to the protection of omeprazole.
TABLE 9: Effect of Herbal composition against pyloric ligation induced Ulcer taking
Ome razole as a Standard dru
TABLE 10: Percentage protection of Herbal composition against pyloric ligation induced Ulcer Model taking Omeprazole as a standard drug.
COMPOUNDS PROTECTION
Herbal composition 124.0
Omeprazole 100
* The protection of Omeprazole was taken as 100 % as it was the standard compound and the percentage protections of other compounds are in respect to the protection of Omeprazole.
Claims
1. A novel synergistic herbal composition for the treatment of gastric ulcer, said composition comprises an extract essentially obtained from the plant parts of Aegle marmelos and Withania somnifra and optionally from the plant parts of Blechnum orintale, Vitis vinifera, Feronia elephantum, Punica grantum, Ziniber officnale, Piper nigrum, Piper longum and Azadirachta indica along with one or more pharmaceutically acceptable additives/carriers.
2. A composition as claimed in claim 1, wherein the composition essentially comprises 4- 10% by wt. of an extract from Aegle marmelos and 4-11 % by wt. of an extract from Withania somnifra and optionally comprises 5-8 % by wt. of an extract from Blechnum orintale, 5-11% by wt. of an extract from Vitis vinifera, 5- 9% by wt. of an extract from Feronia elephantum, 8-11%> by wt. of an extract from Punica grantum, 4-9% by wt. of an extract from Ziniber officnale, 2-11% by wt. of an extract from Piper nigrum, 8-12% by wt. of an extract from Piper longum and 2-
11%) by wt. of an extract from Azadirachta indica along with one or more pharmaceutically acceptable additives/carriers.
3. A composition as claimed in claim 1, wherein the extract is an aqueous extract.
4. A composition as claimed in claim 1, wherein the plant part of Aegle marmelos, Withania somnifra and Blechnum orintale is root.
5. A composition as claimed in claim 1, wherein the plant part of Vitis vinifera, Feronia elephantum, Piper nigrum and Piper longum is fruit.
6. A composition as claimed in claim 1, wherein the plant part of Punica grantum is fruit rind.
7. A composition as claimed in claim 1, the plant part of Ziniber officnale is rhizome.
8. A composition as claimed in claim 1, the plant part of Azadirachta indica is bark.
9. A process for the preparation of the novel synergistic herbal composition for the treatment of gastric ulcer, said process comprising obtaining an extract essentially from the plant parts of Aegle marmelos and Withania somnifra and optionally from the plant parts of Blechnum orintale, Vitis vinifera, Feronia elephantum, Punica grantum, Ziniber officnale, Piper nigrum, Piper longum and Azadirachta indica and mixing them with one or more pharmaceutically acceptable additives/carriers.
10. A process as claimed in claim 9, wherein said extract is obtained by grinding 4- 10% by wt. of an extract from Aegle marmelos and 4-11% by wt. of an extract from
Withania somnifra and optionally 5-8 % by wt. of an extract from Blechnum orintale, 5-11% by wt. of an extract from Vitis vinifera, 5-9% by wt. of an extract from Feronia elephantum, 8-11% by wt. of an extract from Punica grantum, 4-9% by wt. of an extract from Ziniber officnale, 2-11% by wt. of an extract from Piper nigrum, 8-12% by wt. of an extract from Piper longum and 2-11% by wt. of an extract from Azadirachta indica to a fine paste and mixing them with one or more pharmaceutically acceptable additives/carriers.
11. A process as claimed in claim 10, wherein the extract is an aqueous extract.
12. A process as claimed in claim 10, wherein the plant part of Aegle marmelos, Withania somnifra and Blechnum orintale is root.
13. A process as claimed in claim 10, wherein the plant part of Vitis vinifera, Feronia elephantum, Piper nigrum and Piper longum is fruits.
14. A process as claimed in claim 10, wherein the plant part of Punica grantum is fruit rinds.
15. A process as claimed in claim 10, wherein the plant part of Ziniber officnale is rhizomes.
16. A process as claimed in claim 10, wherein the plant part of Azadirachta indica is bark.
17. A method of treating gastric ulcer in a subject, said method comprises administering an effective amount of the synergistic herbal composition essentially comprises 4-10% by wt. of an extract from Aegle marmelos and 4-11% by wt. of an extract from Withania somnifra and optionally comprises 5-8 % by wt. of an extract from Blechnum orintale, 5-11% by wt. of an extract from Vitis vinifera, 5- 9% by wt. of an extract from Feronia elephantum, 8-11% by wt. of an extract from Punica grantum, 4-9% by wt. of an extract from Ziniber officnale, 2-11% by wt. of an extract from Piper nigrum, 8-12% by wt. of an extract from Piper longum and 2- 11%) by wt. of an extract from Azadirachta indica along with one or more pharmaceutically acceptable additives/carriers.
18. A method as claimed in claim 17, wherein the subject is a mammal including human being.
19. A method as claimed in claim 17, wherein 50 to lOOmg of the composition is administered per Kg of body weight to the subject.
20. A method as claimed in claim 17, wherein the composition can be in the form of tablets, capsules, syrup or by any other form known in the art.
21. A method as claimed in claim 17, wherein the composition is administered orally, intra-muscularly, and by any other conventional methods.
22. A method as claimed in claim 17, wherein the composition may be used for therapeutic as well as prophylactic treatment of gastric ulcer.
23. A method as claimed in claim 17, wherein the subject may be administered a single bolus dose or a multiple dose.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2002/001122 WO2003080086A1 (en) | 2002-03-25 | 2002-03-25 | A composition for treating gastric ulcer and a process for preparing the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP1490079A1 true EP1490079A1 (en) | 2004-12-29 |
Family
ID=28053158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP02716987A Withdrawn EP1490079A1 (en) | 2002-03-25 | 2002-03-25 | A composition for treating gastric ulcer and a process for preparing the same |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1490079A1 (en) |
| JP (1) | JP2005526791A (en) |
| CN (1) | CN1627953A (en) |
| AU (1) | AU2002247908A1 (en) |
| CA (1) | CA2480223C (en) |
| WO (1) | WO2003080086A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6713092B1 (en) * | 2002-12-03 | 2004-03-30 | Natreon Inc. | Withania Somnifera composition, method for obtaining same and pharmaceutical, nutritional and personal care formulations thereof |
| WO2014010658A1 (en) * | 2012-07-11 | 2014-01-16 | 興和株式会社 | Preparation containing indian long pepper |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08295632A (en) * | 1995-03-02 | 1996-11-12 | Takeda Chem Ind Ltd | Antibacterial agent |
| IN188667B (en) * | 1995-06-14 | 2002-10-26 | Council Scient Ind Res | |
| FR2775686B1 (en) * | 1998-03-09 | 2006-07-28 | Pascal Commenil | INDUSTRIAL AND COMMERCIAL EXPLOITATION OF CUTICULAR LIPIDS IN THE BAY OF GRAPE IN PHARMACOLOGY AND COSMETOLOGY |
| US6291517B1 (en) * | 1999-11-19 | 2001-09-18 | Dry Creek Nutrition, Inc | Method for preventing or reducing stress-induced gastric injury using grape seed proanthocyanidin extract |
-
2002
- 2002-03-25 CN CNA028290011A patent/CN1627953A/en active Pending
- 2002-03-25 WO PCT/IB2002/001122 patent/WO2003080086A1/en not_active Ceased
- 2002-03-25 CA CA2480223A patent/CA2480223C/en not_active Expired - Fee Related
- 2002-03-25 EP EP02716987A patent/EP1490079A1/en not_active Withdrawn
- 2002-03-25 JP JP2003577912A patent/JP2005526791A/en active Pending
- 2002-03-25 AU AU2002247908A patent/AU2002247908A1/en not_active Abandoned
Non-Patent Citations (1)
| Title |
|---|
| See references of WO03080086A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2480223C (en) | 2011-06-21 |
| JP2005526791A (en) | 2005-09-08 |
| WO2003080086A1 (en) | 2003-10-02 |
| CA2480223A1 (en) | 2003-10-02 |
| CN1627953A (en) | 2005-06-15 |
| AU2002247908A1 (en) | 2003-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Upadhyay et al. | Tinospora cordifolia (Willd.) Hook. f. and Thoms.(Guduchi)–validation of the Ayurvedic pharmacology through experimental and clinical studies | |
| Hedberg et al. | Inventory of plants used in traditional medicine in Tanzania. Part III. Plants of the families Papilionaceaevitaceae | |
| AU2001250634B8 (en) | An improved herbal composition having antiallergic properties and a process for the preparation thereof | |
| Khan et al. | Medicinal use of the unique plant Tinospora cordifolia: evidence from the traditional medicine and recent research | |
| Gupta et al. | Withania coagulans Dunal (paneer doda): A review | |
| Meshram et al. | Potential role of Tinospora cordifolia in pharmaceuticals | |
| US6365198B1 (en) | Pharmaceutical preparation for the treatment of gastrointestinal ulcers and hemorrhoids | |
| Sharma et al. | A comprehensive review of the pharmacological actions of Asparagus racemosus | |
| Widowati et al. | The use of betel (Piper betle) leaves for maintaining the health of women and children at various ethnic groups in Indonesia | |
| Onasanwo et al. | Anti-ulcerogenic and proton pump (H+, K+ ATPase) inhibitory activity of Kolaviron from Garcinia kola Heckel in rodents | |
| Ezeonwumelu et al. | Phytochemical screening, acute toxicity, anti-inflammatory and antipyretic studies of aqueous extract of the root of Flueggea virosa (Roxb. ex Willd.) in rats | |
| US20050287235A1 (en) | Antiulcer herbal compositions | |
| US6855347B2 (en) | Composition for treating gastric ulcer and a process for preparing the same | |
| JP2599160B2 (en) | Preventive and therapeutic agent for staphylococcal disease in chickens | |
| CA2480223C (en) | A composition for treating gastric ulcer and a process for preparing the same | |
| JP2535555B2 (en) | Agent for preventing and treating streptococcal disease in fish | |
| US20120121736A1 (en) | Composition for treating gastric ulcer and a process thereof | |
| US20060141061A1 (en) | Anti-arthritic herbal composition and method thereof | |
| US7651705B2 (en) | Herbal composition for the treatment of gastric ulcer | |
| Ezeonwumelu et al. | Phytochemical screening, acute toxicity and analgesic properties of aqueous extract of flueggea virosa's root in rats | |
| Sharma et al. | Ethnopharmacological importance of Asparagus racemosus: A review | |
| Wakodkar et al. | Herbal potentials for treatment of peptic ulcers: a review | |
| JP2958198B2 (en) | Analgesic pharmaceutical composition | |
| Kushwah et al. | Review on Medicinal value of Asparagus racemosus in Woman's | |
| Van Anh et al. | 9. Gastroprotective effect of Vien Khoi Tim capsules on indomethacin-induced gastric ulcers in rats |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20041025 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
| AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: ARYA VAIDYA SALA Owner name: COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH |
|
| 17Q | First examination report despatched |
Effective date: 20091112 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20100831 |